FDA Expands Guselkumab Label in PsA - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Expands Guselkumab Label in PsA

Phase 3b APEX findings support the addition of structural joint damage inhibition data to the prescribing information.

  • By

  • Kathryn Wighton

  • May 29, 2026

  • 2 min

Share

Clinical Scorecard: FDA Expands Guselkumab Label in PsA

At a Glance

CategoryDetail
ConditionActive Psoriatic Arthritis (PsA)
Key MechanismsInhibition of structural joint damage progression
Target PopulationAdults with active psoriatic arthritis at risk for joint damage
Care SettingOutpatient care for biologic-naïve patients

Key Highlights

  • Guselkumab approved for inhibition of structural joint damage in PsA
  • Supported by phase 3b APEX trial results
  • 57% reduction in radiographic progression from weeks 24 to 48 for patients switching from placebo
  • No new safety signals identified
  • Only interleukin-23 inhibitor with structural inhibition in US prescribing information

Guideline-Based Recommendations

Diagnosis

  • Diagnosis of PsA based on clinical criteria and imaging

Management

  • Guselkumab as a treatment option for patients with inadequate response to standard therapies

Monitoring & Follow-up

  • Monitor for joint symptoms and progression of structural damage

Risks

  • Potential for irreversible joint damage if untreated

Patient & Prescribing Data

Biologic-naïve adults with active PsA

Guselkumab shows significant efficacy in reducing joint symptoms and structural damage

Clinical Best Practices

    Related Resources & Content

    Original Source(s)

    FDA Expands Guselkumab Label in PsA

    • by Kathryn Wighton

    • May 29, 2026

    Related Content

    Does TYK2/JAK1 Show Potential in Inflammatory Diseases?

    Investigational inhibitor was not associated with treatment-related serious adverse events and produced biomarker changes consistent with pathway inhibition in healthy volunteers.

    Wearables May Boost T2D Mobility

    Outpatient intervention combined physiotherapist counseling with wrist-worn activity monitoring.

    Inside the hip osteoarthritis microbiome

    Investigators compared intra-articular microbial profiles and predicted metabolic pathways in patients with hip osteoarthritis and nonarthritic controls.